NCT04987658View on ClinicalTrials.gov

Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 22, 2021

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions
Bipolar I Disorder
Interventions
DRUG

OLZ/SAM

Olanzapine and Samidorphan taken once daily over a max period of 21 days

Trial Locations (2)

30030

Alkermes Investigational Site, Decatur

45219

Alkermes Clinical Investigative Site, Cincinnati

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY